Fig. 7
From: Enhancing immune responses of ESC-based TAA cancer vaccines with a novel OMV delivery system
Scheme illustration of the OMV delivery of TAAs and PD-L1 antibodies targeting tumors. Mice were s.c. injected with OMVs conjugated with both SpT-epitopes and PD-L1 antibodies. After being recognized by APCs, the selected ESC-based epitopes induced the activation of T cells, triggering the enrichment of activated immune cells in tumor tissues, while the delivery of PD-L1 antibody blocked PD-1 signaling to rescue the deactivated T cells, leading to effective specific T cell immunity against the tumor